Gary Gintant, PhD, Abbvie, is optimistic that further advancements in the use of hiPSC - cardiomyocytes will significantly reduce the need for cardiovascular safety testing in animals, but there remains much to be learned about hiPSC - cardiomyocytes to understand the proper conditions for their use in preclinical safety testing. (sciencedaily.com)
The in vivo - like pathophysiology observed in this system suggests that it might serve as a useful tool for evaluating human - relevant renal toxicity in preclinical safety studies. (emulatebio.com)
Performs genome - wide profiling of vector integration sites as readout of cell growth at clonal level, in basic research studies and technology development, in preclinical safety studies and in gene therapy treated patients. (research.hsr.it)